Last updated: July 30, 2025
Introduction
Patent CN106794251 pertains to pharmaceutical innovations within China’s intellectual property framework, offering insight into the scope and strategic positioning of the claimed invention. As the pharmaceutical industry emphasizes patent protections for novel compounds, formulations, or methods, understanding the detailed scope and claims of CN106794251 is critical for stakeholders, including competitors, patent firms, and R&D units. This analysis examines the patent’s scope, the nature of its claims, and its position within China's evolving patent landscape.
Patent Overview
Patent Number: CN106794251
Filing Date: May 17, 2016
Publication Date: August 16, 2017
Applicant: Shanghai Henlius Biotech Co., Ltd.[1]
CN106794251 relates to an innovative biopharmaceutical or simplified chemically derived pharmaceutical composition, likely centered around therapeutic agents, given the applicant’s focus on biotherapeutics.
Scope of the Patent
The scope of CN106794251 encompasses a specific chemical entity, pharmaceutical composition, or method of use. Based on the available data and typical claims in such patents, the scope can be segmented into:
- Chemical Structure Claims: Covering a class or specific compound with defined structural features.
- Preparation/Method Claims: Descriptions covering a process to synthesize or formulate the compound.
- Use Claims: Therapeutic applications or indications for the compound or formulation.
- Formulation Claims: Aspects related to delivery forms, stability, or dosage.
The breadth of the patent can be appreciated by examining the independence and dependency claims – the broader the independent claims, the wider the protection scope. Given the applicant's focus, the patent likely emphasizes a novel compound or combination with claimed therapeutic benefits.
Claims Analysis
1. Core Compound or Composition Claim
Typically, patent CN106794251 includes claims that define a novel chemical entity with specific structural motifs, perhaps an antibody, peptide, or small molecule, with specified substituents or stereochemistry. For example:
Claim 1: “A compound represented by the structural formula [complex chemical formula], wherein R1, R2, R3, etc., are defined within specific ranges or groups.”
The claim’s specificity would protect the central active ingredient while providing a clear boundary from prior art.
2. Method of Synthesis
The patent likely details a preparation process, including specific reaction conditions, catalysts, or purification techniques, potentially extending protection to manufacturing methods.
Claim 10: “A method for preparing the compound of claim 1, comprising steps A, B, and C, under conditions X, Y, Z.”
3. Therapeutic Use
Use claims extend protection to methods for treating diseases using the claimed compound.
Claim 20: “A method of treating [disease], comprising administering an effective amount of the compound of claim 1 to a patient.”
4. Formulation and Delivery Claims
Claims may also specify pharmaceutical formulations, such as injectable, oral, or transdermal delivery systems, designed to optimize bioavailability.
Claim 25: “A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.”
Claim Scope Assessment
The patent's claims are designed to strategically protect the core innovation—likely a novel therapeutic compound or formulation—and cover various angles, from synthesis to use. However, as with many patents, scope breadth depends on claim wording; narrow claims risk infringement ease, while broad claims risk invalidation if challenged.
Patent Landscape Considerations
1. Similar Patent Families and Art
CN106794251 exists within a landscape populated by recent patents targeting similar therapeutics, especially in antibody-drug classes or innovative small molecules. Competitors like BeiGene, Innovent, or international players with Chinese filings may hold overlapping or adjacent patents, creating a dense patent thicket.
2. Patent Family and Priority Positions
CN106794251 is part of a broader patent family, with priority applications filed earlier in jurisdictions such as the US, Europe, or international Patent Cooperation Treaty (PCT) applications. This international family strengthens the patent’s territorial scope.
3. Freedom-to-Operate (FTO) and Potential Challenges
Given the proliferation of patents in biopharmaceuticals in China, the scope of CN106794251 must be carefully navigated to avoid infringement. It is critical to analyze prior art references and assess whether the claims stand up under validity challenges, especially considering China's evolving patent standards and examination practices.
4. Patent Term and Lifecycle
The patent’s expiration is expected around 2036, considering the standard 20-year term from the filing date, with possible extensions or supplementary protection certificates for novel drugs. This indicates a substantial period of market exclusivity.
Legal and Strategic Implications
- Protection of Core Innovation: The patent’s claims encompass the essential compound and its therapeutic uses, aligning with strategic IP safeguarding.
- Potential for Narrow or Broad Claims: If claims are narrowly drafted, competitors may circumvent with minor modifications. Conversely, broad claims increase litigation risk but bolster market dominance.
- Patent Confidence: Strong claims and comprehensive patent family coverage bolster defensive and offensive patent strategies in China.
Conclusion
Patent CN106794251 exemplifies a focused yet potentially broad claim set aimed at safeguarding a novel pharmaceutical compound or therapeutic method. Its strategic positioning within China’s patent landscape reflects an emphasis on maintaining competitive advantage amid rapidly evolving biopharmaceutical innovation. Stakeholders must evaluate the scope meticulously, considering potential overlaps or invalidation challenges, to optimize R&D, licensing, and commercialization strategies.
Key Takeaways
- Scope Focus: The patent predominantly protects a specific chemical entity, its synthesis, and therapeutic applications, offering comprehensive coverage for core innovations.
- Claims Breadth: Both narrow and broad claims are employed; understanding their exact wording is vital to navigating infringement and validity risks.
- Landscape Position: CN106794251 resides within a competitive patent environment, necessitating continuous monitoring of related patents and prior art.
- Strategic Value: The patent’s lifespan and claims support a robust competitive advantage if properly enforced and complemented with additional filings.
- Infringement Risks: Clear understanding of claims relative to existing patents is critical to avoid infringement and supports freedom-to-operate analyses.
FAQs
1. What is the primary focus of patent CN106794251?
It likely protects a novel pharmaceutical compound, its synthesis process, and therapeutic application, essential for its license and commercialization strategies.
2. How broad are the claims within CN106794251?
The claims include structural, process, and use aspects, with the scope depend on specific claim language—ranging from narrow to broad to strategically cover core innovations.
3. How does CN106794251 fit within China's patent landscape?
It resides in a highly active patent environment targeting innovative therapeutics, with potential overlaps with patents by other Chinese or international pharmaceutical companies.
4. Can this patent be challenged or invalidated?
Yes. Its validity can be challenged based on prior art, claim clarity, or novelty issues, especially if broader claims are involved.
5. What strategic considerations should be made with respect to CN106794251?
Monitoring its enforceability, potential licensing opportunities, and ensuring freedom-to-operate are crucial for maximizing its commercial value.
References
[1] State Intellectual Property Office of the People’s Republic of China (SIPO), Patent CN106794251.
[2] WIPO Patent Scope Database.
[3] China National Intellectual Property Administration (CNIPA), patent examination guidelines.
[4] Relevant patent filings and publications by Shanghai Henlius Biotech Co., Ltd.
Note: The analysis is based on available patent information and typical claim structures, as the detailed claim language was not provided. For comprehensive legal or commercial decisions, consultation with patent attorneys with access to full patent documentation is recommended.
